Searched for: in-biosketch:true
person:bls322
Changes in abundance of oral microbiota associated with oral cancer
Schmidt, Brian L; Kuczynski, Justin; Bhattacharya, Aditi; Huey, Bing; Corby, Patricia M; Queiroz, Erica L S; Nightingale, Kira; Kerr, A Ross; DeLacure, Mark D; Veeramachaneni, Ratna; Olshen, Adam B; Albertson, Donna G
Individual bacteria and shifts in the composition of the microbiome have been associated with human diseases including cancer. To investigate changes in the microbiome associated with oral cancers, we profiled cancers and anatomically matched contralateral normal tissue from the same patient by sequencing 16S rDNA hypervariable region amplicons. In cancer samples from both a discovery and a subsequent confirmation cohort, abundance of Firmicutes (especially Streptococcus) and Actinobacteria (especially Rothia) was significantly decreased relative to contralateral normal samples from the same patient. Significant decreases in abundance of these phyla were observed for pre-cancers, but not when comparing samples from contralateral sites (tongue and floor of mouth) from healthy individuals. Weighted UniFrac principal coordinates analysis based on 12 taxa separated most cancers from other samples with greatest separation of node positive cases. These studies begin to develop a framework for exploiting the oral microbiome for monitoring oral cancer development, progression and recurrence.
PMCID:4041887
PMID: 24887397
ISSN: 1932-6203
CID: 1030742
Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma
Viet, Chi T; Dang, Dongmin; Achdjian, Stacy; Ye, Yi; Katz, Samuel G; Schmidt, Brian L
Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance. We determined whether a demethylating drug, decitabine, could augment the anti-proliferative and apoptotic effects of cisplatin on SCC-25/CP, a cisplatin-resistant tongue SCC cell line. We showed that decitabine treatment restored cisplatin sensitivity in SCC-25/CP and significantly reduced the cisplatin dose required to induce apoptosis. We then created a xenograft model with SCC-25/CP and determined that decitabine and cisplatin combination treatment resulted in significantly reduced tumor growth and mechanical allodynia compared to control. To establish a gene classifier we quantified methylation in cancer tissue of cisplatin-sensitive and cisplatin-resistant HNSCC patients. Cisplatin-sensitive and cisplatin-resistant patient tumors had distinct methylation profiles. When we quantified methylation and expression of genes in the classifier in HNSCC cells in vitro, we showed that decitabine treatment of cisplatin-resistant HNSCC cells reversed methylation and gene expression toward a cisplatin-sensitive profile. The study provides direct evidence that decitabine restores cisplatin sensitivity in in vitro and in vivo models of HNSCC. Combination treatment of cisplatin and decitabine significantly reduces HNSCC growth and HNSCC pain. Furthermore, gene methylation could be used as a biomarker of cisplatin-resistance.
PMCID:4229295
PMID: 25391133
ISSN: 1932-6203
CID: 1648482
Methylation as a mechanism of cisplatin resistance in head and neck cancer [Meeting Abstract]
Viet, C T; Dang, D; Ye, Y; Schmidt, B L
Cisplatin is the primary chemotherapy for head and neck squamous cell carcinoma (HNSCC). No equally effective chemotherapeutics are available when cisplatin resistance occurs. We hypothesize that DNA methylation of key genes mediates cisplatin resistance; moreover, pretreatment with decitabine, a demethylating agent, restores cisplatin sensitivity by mediating expression of genes that are instrumental to cisplatin resistance. Objectives: 1) Determine whether decitabine treatment of a cisplatin-resistant HNSCC cell line restores the anti-proliferative and apoptotic effects of cisplatin; 2) Evaluate the anti-proliferative effect of decitabine and cisplatin (i.e. combination treatment) on a preclinical HNSCC model; 3) Determine whether combination treatment reduces cancer pain; and 4) Create a "gene expression profile of cisplatin resistance" by analyzing cisplatinsensitive and cisplatin-resistant HNSCC in patients. Methods: SCC-25, a cisplatin-sensitive HNSCC cell line, and SCC-25/CP, a cisplatin-resistant cell line, were pre-treated with 5mM decitabine and then treated with cisplatin (3-300 mM) for 48 hours. Proliferation was quantified with an MTS assay. Apoptosis was quantified with a caspase 3/7 assay. A preclinical model was created by inoculating SCC-25/CP cells into the hind-paw of BALB/ c mice. Twenty-four mice were placed into one of four treatment groups: control sham, decitabine-only, cisplatin- only, or combination treatment. Decitabine (6 mg/kg) was administered on post-inoculation days (PID) seven and nine, and cisplatin (6 mg/kg) was administered on PID 12, 15, 18, and 21. Tumor growth was quantified. Mechanical allodynia (i.e. pain) was quantified with a paw withdrawal assay. Formalin-fixed, paraffin- embedded biopsies were obtained from HNSCC patients who underwent chemotherapy with cisplatin. Tumors were classified as either cisplatin-sensitive (RECIST 3 or 4) or cisplatin-resistant (RECIST 1 or 2). Gene expression was quantified in these two sets of samples. Results: In the in !
EMBASE:71166045
ISSN: 0278-2391
CID: 549502
Quality of life after maxillectomy and prosthetic obturator rehabilitation
Chigurupati, Radhika; Aloor, Neelam; Salas, Richard; Schmidt, Brian L
PURPOSE: Surgical resection of midface neoplasms and subsequent reconstruction have been shown to have significant negative effects on quality of life (QOL). The purpose of this pilot study was to assess individuals' health-related QOL after maxillectomy and reconstruction with a prosthetic obturator. MATERIALS AND METHODS: The QOL of 25 of 43 patients who underwent maxillectomy and prosthetic obturator reconstruction at the University of California-San Francisco was assessed using 3 questionnaires: University of Washington Quality of Life version 4 (UWQOL), Obturator Functioning Scale (OFS), and Mental Health Inventory (MHI). RESULTS: The response rate to the QOL questionnaires was 92% (23 of 25 patients). Time elapsed from maxillectomy and prosthetic obturator reconstruction to the QOL survey response ranged from 0.3 to 6.6 years (mean, 2.7 years; standard deviation [SD], 1.9 years). The post-treatment mean QOL scores were 77.3 (SD, 13.6) for UWQOL, 72.0 (SD, 12.6) for OFS, and 4.5 (SD, 0.9) for Mental Health Inventory. Individuals who received adjuvant radiation scored lower for speech and appearance (OFS, P = .05, P = .03, respectively) as well as for saliva and overall QOL (UWQOL, P = .02, P = .08, respectively). There was a strong correlation between QOL scores in OFS and UWQOL questionnaires (r = 0.78, P < .001). CONCLUSION: The results of this pilot study suggest that postoperative radiation therapy was the strongest variable affecting QOL in patients with maxillectomy and prosthetic obturator reconstruction. There is further need for a multicenter trial with a larger sample to identify how factors affecting QOL of patients after maxillectomy might influence the choice of reconstruction.
PMID: 23540428
ISSN: 1531-5053
CID: 1648492
Informationist Support for a Study of the Role of Proteases and Peptides in Cancer Pain
Surkis, Alisa; McCrillis, Aileen; McGowan, Richard; Williams, Jeffrey; Schmidt, Brian L; Hardt, Markus; Rambo, Neil
Two supplements were awarded to the New York University Health Sciences Libraries from the National Library of Medicine's informationist grant program. These supplements funded research support in a number of areas, including data management and bioinformatics, two fields that the library had recently begun to explore. As such, the supplements were of particular value to the library as a testing ground for these newer services. This paper will discuss a supplement received in support of a grant from the National Institute of Dental and Craniofacial Research (PI: Brian Schmidt) on the role of proteases and peptides in cancer pain. A number of barriers were preventing the research team from maximizing the efficiency and effectiveness of their work. A critical component of the research was to identify which proteins, from among hundreds identified in collected samples, to include in preclinical testing. This selection involved laborious and prohibitively time-consuming manual searching of the literature on protein function. Additionally, the research team encompassed ten investigators working in two different cities, which led to issues around the sharing and tracking of both data and citations. The supplement outlined three areas in which the informationists would assist the researchers in overcoming these barriers: 1) creating an automated literature searching system for protein function discovery, 2) introducing tools and associated workflows for sharing citations, and 3) introducing tools and workflows for sharing data and specimens
ORIGINAL:0008127
ISSN: 2161-3974
CID: 306492
Lymphatic and Angiogenic Candidate Genes Predict the Development of Secondary Lymphedema following Breast Cancer Surgery
Miaskowski, Christine; Dodd, Marylin; Paul, Steven M; West, Claudia; Hamolsky, Deborah; Abrams, Gary; Cooper, Bruce A; Elboim, Charles; Neuhaus, John; Schmidt, Brian L; Smoot, Betty; Aouizerat, Bradley E
The purposes of this study were to evaluate for differences in phenotypic and genotypic characteristics in women who did and did not develop lymphedema (LE) following breast cancer treatment. Breast cancer patients completed a number of self-report questionnaires. LE was evaluated using bioimpedance spectroscopy. Genotyping was done using a custom genotyping array. No differences were found between patients with (n = 155) and without LE (n = 387) for the majority of the demographic and clinical characteristics. Patients with LE had a significantly higher body mass index, more advanced disease and a higher number of lymph nodes removed. Genetic associations were identified for four genes (i.e., lymphocyte cytosolic protein 2 (rs315721), neuropilin-2 (rs849530), protein tyrosine kinase (rs158689), vascular cell adhesion molecule 1 (rs3176861)) and three haplotypes (i.e., Forkhead box protein C2 (haplotype A03), neuropilin-2 (haplotype F03), vascular endothelial growth factor-C (haplotype B03)) involved in lymphangiogensis and angiogenesis. These genetic associations suggest a role for a number of lymphatic and angiogenic genes in the development of LE following breast cancer treatment.
PMCID:3629060
PMID: 23613720
ISSN: 1932-6203
CID: 316182
Results of a 950-patient phase 2/3 clinical characterization-association study to classify patients with Potentially Malignant Oral Disorders (PMODs) using a non-invasive Lab-On-a-Chip (LOC) approach [Meeting Abstract]
Floriano, Pierre N; Kerr, ARoss; Schmidt, Brian L; Corby, Patricia; Castilla, Ismael El Khouly; Thornhill, Martin H; D'Apice, Katy; Murdoch, Craig; Speight, Paul; Redding, Spencer; McGuff, Stan; Yeh, Chih-K O; Westbrook, Steve; Diburro, Mark; Rowan, Stephanie; Vigneswaran, Nadarajah; Weinstock, Etan Y; Demian, Nagi; Nguyen, Tammy Tran; Sanchez, Maga; Christodoulides, Nicolaos; Gaur, Surabhi; Karthikeyan, Kailash; Talavera, Humberto; Nguyen, Michael; Le, Cathy; Taylor, Leander; McDevitt, John T
ISI:000209477200182
ISSN: 1879-0593
CID: 2344672
Molecular Biology of Head and Neck Cancer: Therapeutic Implications
Chapter by: Lam, David K.; Schmidt, Brian L.
in: Current Therapy in Oral and Maxillofacial Surgery by
[S.l.] : Elsevier Inc., 2012
pp. 92-101
ISBN: 9781416025276
CID: 2868262
Identification of patient subgroups and risk factors for persistent breast pain following breast cancer surgery
Miaskowski, Christine; Cooper, Bruce; Paul, Steven M; West, Claudia; Langford, Dale; Levine, Jon D; Abrams, Gary; Hamolsky, Deborah; Dunn, Laura; Dodd, Marylin; Neuhaus, John; Baggott, Christina; Dhruva, Anand; Schmidt, Brian; Cataldo, Janine; Merriman, John; Aouizerat, Bradley E
Study purposes were to determine the prevalence of persistent pain in the breast; characterize distinct persistent pain classes using growth mixture modeling; and evaluate for differences among these pain classes in demographic, preoperative, intraoperative, and postoperative characteristics. In addition, differences in the severity of common symptoms and quality of life outcomes measured prior to surgery, among the pain classes, were evaluated. Patients (n = 398) were recruited prior to surgery and followed for 6 months. Using growth mixture modeling, patients were classified into no (31.7%), mild (43.4%), moderate (13.3%), and severe (11.6%) pain groups based on ratings of worst breast pain. Differences in a number of demographic, preoperative, intraoperative, and postoperative characteristics differentiated among the pain classes. In addition, patients in the moderate and severe pain classes reported higher preoperative levels of depression, anxiety, and sleep disturbance than the no pain class. Findings suggest that approximately 25% of women experience significant and persistent levels of breast pain in the first 6 months following breast cancer surgery. PERSPECTIVE: Persistent pain is a significant problem for 25% of women following surgery for breast cancer. Severe breast pain is associated with clinically meaningful decrements in functional status and quality of life.
PMCID:3511823
PMID: 23182226
ISSN: 1526-5900
CID: 202502
Novel Animal Models of Acute and Chronic Cancer Pain: A Pivotal Role for PAR2
Lam, David K; Dang, Dongmin; Zhang, Jianan; Dolan, John C; Schmidt, Brian L
Targeted therapy to prevent the progression from acute to chronic pain in cancer patients remains elusive. We developed three novel cancer models in mice that together recapitulate the anatomical, temporal, and functional characteristics of acute and chronic head and neck cancer pain in humans. Using pharmacologic and genetic approaches in these novel cancer models, we identified the interaction between protease-activated receptor 2 (PAR2) and serine proteases to be of central importance. We show that serine proteases such as trypsin induce acute cancer pain in a PAR2-dependent manner. Chronic cancer pain is associated with elevated serine proteases in the cancer microenvironment and PAR2 upregulation in peripheral nerves. Serine protease inhibition greatly reduces the severity of persistent cancer pain in wild-type mice, but most strikingly, the development of chronic cancer pain is prevented in PAR2-deficient mice. Our results demonstrate a direct role for PAR2 in acute cancer pain and suggest that PAR2 upregulation may favor the development and maintenance of chronic cancer pain. Targeting the PAR2-serine protease interaction is a promising approach to the treatment of acute cancer pain and prevention of chronic cancer pain.
PMCID:3500608
PMID: 23055487
ISSN: 0270-6474
CID: 184392